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A STUDY ON THE LOCALIZATION OF ALTERNATIVE MEFV 
TRANSCRIPTS IN NEUTROPHIL-LIKE CELLS 
 
SUMMARY 
Familial Mediterranean Fever (FMF) is an inflammatory disease which generally 
affects people of Mediterranean heritage. It is characterized by attacks of fever with 
serositis. MEFV, which is gene of FMF, spans a 15-kb interval on chromosome 16p, 
contains 10 exons that comprise a 3.7-kb transcript, and encodes a 781– amino acid 
protein named pyrin/marenostrin (P/M). Although the exact mechanism of 
pyrin/marenostrin is not known, its importance in the inflammatory pathway is well 
established. P/M is expressed in neutrophils, eosinophils, monocytes, dendritic cells 
and synovial fibroblasts.  
 Alternative splicing, which is one of the mechanisms that increases protein diversity, 
is the process by which multiple mRNAs can be generated from the same pre-mRNA 
by the differential joining of 5’ and 3’ splice sites. There are fifteen MEFV 
transcripts which are generated by alternative splicing: full-length (fl), 2Δ (d2), 2a, 
4a, 8ext, 2Δ/4a, 2Δ/8ext, 2Δ/9ext, 2a/4a, 2a/8ext, del2.3.4, del2.3.4 del7, del2.3.4 
del7.8, del2.3.4.5, del3.4 del7.8. Among these MEFV alternative transcripts only 
seven transcripts can be translated to proteins: Fl, 2Δ, 2Δ/8ext, 2Δ/9ext, 8ext, 2a, 
2a/4a. A previous study carried out by our group has shown that exon 2 deleted form 
(2Δ) in FMF patients is expressed significantly higher compared to healty controls 
(p=0.026).  
The subcellular localization of full-length P/M and P/M-2Δ isoform was investigated 
in several cell lines and in literature these studies showed that full-length P/M was 
cytoplasmic and 2Δ isoform was nuclear except one study. This study indicated that 
myc-tagged 2Δ was not exclusively nuclear and were more often cytoplasmic in 
synovial fibroblasts. It also showed that native P/M which consists of predominantly 
full-length type, was predominantly nuclear in synovial fibroblasts, neutrophils, and 
dendritic cells, but was cytoplasmic in monocytes. Moreover, the localization of 
P/M-fl and P/M-2Δ  was not affected by most frequent MEFV mutations. 
These findings have led us to hypothesize the role of  MEFV 2Δ isoform in the 
disease pathology. To this end two GFP-tagged plasmids which are MEFV-fl-GFP 
and  MEFV-d2-GFP were transfected to HL-60 (Human promyelocytic leukemia 
cells) cell line first, and their localization were detected with confocal microscope. 
Subsequently, HL-60 cells were differentiated to  neutrophil-like cells via DMSO. 
Cell differentiation was confirmed via flow cytometry assay. These cells were also 
transfected with same plasmids and proteins were observed through confocal 
microscopy technique. 
Our results showed that MEFV-fl-GFP was localized in cytoplasm of the cell and 
MEFV-d2-GFP was localized in nucleus of HL-60 cell line. On the other hand, both 
xx 
 
MEFV-fl-GFP and MEFV-d2-GFP were localized in cytoplasm of neutrophil-like 
cells. Inability of MEFV-d2-GFP form to localize into nucleus in neutrophil-like 
cells in vitro together with its high expression in FMF patients in vivo strenghten our 
hypothesis of MEFV exon 2 deleted transcripts pathologic role in FMF.    
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MEFV ALTERNATİF TRANSKRİPTLERİNİN NÖTROFİL BENZERİ 
HÜCRELERDE LOKALİZASYON ÇALIŞMASI 
 
ÖZET 
Ailesel Akdeniz Ateşi (AAA) hastalığı, genellikle Akdeniz toplumlarını (Yahudiler, 
Araplar, Türkler, Ermeniler, vb.) etkileyen inflamatuar bir hastalıktır. Çoğunlukla 
peritonite eşlik eden ateş atakları ile kendini göstermektedir.  
AAA hastalığının geni olan MEFV; 16. kromozomun kısa kolunun 15kb’lık kısmını 
kapsar. MEFV, nükleer efektör moleküllerin, onkojenezi, embriyonik gelişimi, 
inflamasyonu ve hematopoezi düzenleyen nükleik aside bağlanan proteinlerin yer 
aldığı, büyük ölçüde korunmuş bir gen ailesine aittir. 10 adet ekzon içeren bu gen  
3.7 kb’lik bir transkript oluşturur ve 781 adet amino asitten oluşan pyrin/marenostrin 
(P/M) proteinini kodlar. Tam mekanizması bilinmemekle birlikte, P/M proteininin 
inflamasyon yolağındaki önemi belirlenmiştir. P/M proteini; nötrofiller, eozinofiller, 
monositler, dendritik hücreler ve sinoviyal fibroblastlarda üretilmektedir. MEFV 
ekspresyonu; interferon γ (IFN-γ), tümör nekrozis faktör α (TNF-α), lipopolisakkarid 
(LPS) ve interlökin 1β (IL-1β) gibi proinflamatuar ajanlar ile artar. 
Bugüne kadar, MEFV geni üzerinde 246 varyasyon belirlenmiştir. Bunların 119 
tanesi AAA hastalığı ile ilişkili bulunmuştur. Gen üzerindeki mutasyonlar; ekzon 1, 
2, 3, 5, 9 ve 10’da yer alır. Mutasyonlar için iki adet sıcak bölge belirlenmiştir: 
Bunlardan bir tanesi ikinci, diğeri de onuncu ekzondur. En çok görülen beş mutasyon 
ise şunlardır: İkinci ekzonda yer alan E148Q, onuncu ekzonda yer alan M694V, 
M680I, M694I ve V726A. 
86 kDa’luk pyrin proteini, 5 bölgeden oluşur: N-ucundaki pyrin (PYD) bölgesi, 
bZIP, B-box, coiled-coil bölgesi, and C-ucundaki B30.2 (PRYSPRY) bölgesi. Her 
bölgenin protein-protein etkileşimlerinde farklı bir görevi vardır. Örneğin; sitokin 
salınımı, transkripsiyonel düzenleme, hücre iskeleti sinyali ve hücre ölümü 
düzenlenmesi vasıtasıyla oluşan inflamasyon bağlantılı proteinlerle etkileşmektedir.  
Protein çeşitliliğinin artırılmasını sağlayan mekanizmalardan biri olan alternatif 
kırpılma, aynı öncül mRNA’dan 5’ ve 3’ kırpılma bölgelerinin farklı birleşimleriyle 
birden fazla mRNA elde edilmesidir. İnsanlarda, çok sayıda ekzon içeren genlerin 
%95’inde alternatif kırpılma gerçekleşmektedir. 
Alternatif kırpılma 6 tipte gruplandırılabilir: (1) kaset-tipi alternatif ekzonlar; (2) 
ekzon dizileri içerisindeki 5’ ya da 3’ kırpılma bölgelerinin alternatif seçilimi; (3) 
karşılıklı hariç tutulan ekzonlar; (4) intron koruma; (5) alternatif promotörler; (6) 
alternatif poliadenilasyon. İnsanlarda, daha çok ekzon atlama tipindeki alterantif 
kırpılma görülmektedir. 
Alternatif kırpılmayla oluşmuş 15 adet MEFV transkripti bulunmaktadır: Tam boy 
(fl), 2Δ (d2), 2a, 4a, 8ext, 2Δ/4a, 2Δ/8ext, 2Δ/9ext, 2a/4a, 2a/8ext, del2.3.4, del2.3.4 
del7, del2.3.4 del7.8, del2.3.4.5, del3.4 del7.8. Alternatif MEFV transkriptleri 
arasında yalnızca yedi tanesi proteine çevrilmektedir: Fl, 2Δ, 2Δ/8ext, 2Δ/9ext, 8ext, 
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2a, 2a/4a. Grubumuzun gerçekleştirdiği önceki bir çalışmada ekzon 2-kırpılmış 
formun (2Δ) ekspresyonunun, AAA hastalarında sağlıklı kontrollere göre anlamlı 
ölçüde yüksek olduğu gösterilmiştir (p=0.026).  
Son dönemde yapılan çalışmalarda, tam boy ve 2Δ (Ekzon 2-kırpılmış) formlarındaki 
pyrin/marenostrin proteinlerinin hücre içi lokasyonları belirli hücrelerde 
araştırılmıştır. Bu çalışmaların ilkinde; COS-1 hücrelerinde tam boy 
pyrin/marenostrin proteininin lokalizasyonunun sitoplazmada olduğu tespit 
edilmiştir. Diğer bir çalışmada; CHO hücrelerinde, tam boy pyrin/marenostrinin 
sitoplazmada lokalize olurken, 2Δ formunun nukleusta yer aldığı gösterilmiştir. Bir 
başka çalışmada; bu iki formun en sık görülen MEFV mutasyonları taşıyan ve 
taşımayanlarının HeLa hücrelerindeki lokalizasyonu karşılaştırılmıştır. Ancak bu 
mutasyonların lokalizasyonda bir değişikliğe sebep olmadığı ve tam boy 
pyrin/marenostrinin sitoplazmada, ekzon-2 kırpılmış formun (2Δ) ise nukleusta 
olduğu gözlenmiştir. Lokalizasyonla ilgili yapılan en yeni çalışmada ise sinoviyal 
fibroblastlara transfekte edilen myc-etiketli tam boy pyrin/marenostrinin 
sitoplazmada, myc etiketli-2Δ izoformunun ise yalnızca nukleus içerisinde değil, 
hatta daha sık olarak sitoplazmada lokalize olduğu gösterilmiştir. Bunun yanında 
doğal pyrin/marenostrin proteininin çoğunluğu tam boy formdan oluştuğu halde, 
doğal protein sinoviyal fibroblastlarda, nötrofillerde ve dendritik hücrelerde ağırlıklı 
olarak nukleusta, monositlerde ise  sitoplazmada saptanmıştır. 
Bu bulgular bize MEFV-2Δ formunun hastalık patolojisinde rolü olduğunu 
varsaymamızı sağladı. Bu amaçla tam boy ve 2Δ izoformunu içeren GFP-etiketli 2 
adet plazmid ilk olarak HL-60 (İnsan promiyolositik lösemi hücreleri) hücre hattına 
transfekte edildi ve proteinlerin lokalizasyonu konfokal mikroskop aracılığıyla 
saptandı. Daha sonra HL-60 hücreleri DMSO ile inkübe edilip nötrofil-benzeri 
hücrelere farklılaştırıldı. 0.5-2x105 hücre/mL olacak şekilde dört farklı hücre 
başlangıç sayısı kullanıldı. 6 gün boyunca %1.25, %1.5 ve %1.75 oranlarında DMSO 
uygulaması yapıldı. İnkübasyonun ilk üç gününde FBS içermeyen medya kullanıldı. 
İnkübasyon sonrası, poly-L-lysine kaplı her lamele 3x105 hücre ekildi. 24 saat sonra 
DAPI ile boyanarak konfokal mikroskop yardımıyla farklılaşma oranı incelendi. En 
iyi sonuç 0.5x105 hücre/mL ile başlanan inkübasyondan elde edildi. ~ %40 oranında 
bir farklılaşma görüldü.  
Hücre farklılaşması akım sitometri yöntemi ile de doğrulandı. Farklılaşma belirteçi 
olarak CD44 antijeni seçildi. Hücre-hücre etkileşiminde, hücre adezyonu ve hücre 
göçü olaylarında yer alan bir hücre yüzeyi glikoproteini olan CD44; hemopoetik 
hücreler de dahil olmak üzere birçok hücre tipinde üretilmektedir. DMSO ile inkübe 
edilerek nötrofile doğru farklılaştırılan HL-60 hücrelerindeki CD44 ekspresyonunun 
düşüşü, normal granülosit oluşumu sırasındaki CD44 azalması ile uyumludur. Bu 
nedenle HL-60 ve DMSO uygulanmış HL-60 (nötrofil-benzeri hücreler) hücreleri 
CD44 ekspresyonu açısından karşılaştırıldı. Bunun sonucunda DMSO ile inkübe 
edilmiş hücrelerde CD44 kaybına rastlandı. Daha sonra farklılaştırılan bu hücreler de 
aynı plazmidler ile transfekte edildi ve proteinler konfokal mikroskopi tekniğiyle 
gözlemlendi.  
Bu çalışmada kullanılan HL-60 hücre hattı; all-trans retinoik asit (ATRA), Dimetil 
Sülfoksit (DMSO), 1α,25-dihidroksivitamin-D3, forbol ester türevleri (TPA) gibi 
ajanların uygulanması ile nötrofil, monosit ve makrofajlara dönüşebilme özelliklerine 
sahip süspansiyon bir kültürdür. Malign hücrelerin özelliklerini gösterir ve 
onkogenleri eksprese eder. Farklılaşmamış HL-60 hücreleri; geniş bir çekirdeğe ve 
çoklu azurofilik granüllere sahip bazofilik bir sitoplazmaya sahiptir. DMSO 
uygulamasıyla farklılaşabildiği nötrofiller ise; at nalı veya segmentli/loblu bir 
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çekirdeğe sahiptir. Sitoplazması içerisinde ise küçük ve açık pembe granüller 
dağılmış durumdadır. Farklılaşma esnasında, HL-60 hücrelerinin çoğalmaları durur, 
yeni genler eksprese etmeye başlar, morfolojik değişime uğrarlar ve sonunda da 
apoptoza giderler. 
Bununla birlikte, pyrin proteinin her iki formunun hücre içerisindeki lokalizasyonları 
western-blot tekniği ile doğrulanmak istendi. Bunun için her iki plazmid de aynı 
hücreye verilerek (hem HL-60, hem de nötrofile farklılaştırılan hücreler) ikili 
transfeksiyon yapıldı. Traansfeksiyondan 24 saat sonra, DMSO uygulanmış ve 
uygulanmamış hücrelerden total, sitoplazmik ve nükleer protein izolasyonları 
gerçekleştirildi. Ancak western-blot sonucunda sitoplazmik ve nükleer proteinlerin 
birbirinden ayrılamadığı görüldü. Bunun kontorolü sitoplazmik bir protein olan b-
actin ve nüklear bir protein olan histone-h3 antikorları ile gerçekleştirildi. 
Bu çalışma sonucu elde ettiğimiz bulgular; tam boy proteinin HL-60 hücrelerinde 
sitoplazmada lokalize olurken, ekzon 2-kırpılmış formun nukleus içerisinde 
olduğunu göstermiştir. Öteki taraftan, nötrofil benzeri hücrelerde durum HL-60 
hücrelerindekinden farklı bir tablo çizmiştir ve her iki form da sitoplazma içerisinde 
lokalize olmuştur. MEFV-d2 formunun nötrofil benzeri hücrelerde nukleus içerisinde 
lokalize olamaması ve bununla birlikte bu formun AAA hastalarında ekspresyonunun 
yüksek olduğu düşünüldüğünde elde edilen bulgular bu izoformun AA hastalığındaki 
patolojik rolü hakkındaki hipotezimizi güçlendirmektedir. 
Bu çalışmanın başka hücre tiplerinde de tekrarlanması gerekmektedir. Örneğin 
MEFV ekspresyonuna sahip ve inflamasyonda görev alan monositik hücre hatları 
(THP-1, U937, vb.), bu iki formu taşıyan plazmidlerle transfekte edilerek nötrofil-
benzeri hücrelerdeki lokalizasyon durumuyla karşılaştırılmalıdır. 
Bununla birlikte protein deteksiyonu, sitoplazma ve nukleusu birbirinden düzgün bir 
biçimde ayırabilecek farklı yöntemler uygulanarak tekrarlanmalıdır. Bu çalışmayı 
desteklemek amacıyla in vitro infeksiyon modeli oluşturulup tam boy ve ekzon 2-
kırpılmış formların loklaizasyonları araştırılabilir. 
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1.  INTRODUCTION 
1.1 MEFV gene and Familial Mediterranean Fever disease 
Familial Mediterranean fever (FMF) is autoinflammatory disease which affects 
primarily Jews, Arabs, Turks and Armenians. The prevalence of FMF in Turkey is 
estimated as 1/1000 [1]. FMF is characterized by recurrent attacks of fever along 
with abdominal pain and serosal inflammation; it is accompanied by skin lesions, 
vasculitis, and amyloidosis in some cases. The molecular mechanisms underlying the 
inflammatory attacks has not been clarified yet [2,3]. 
MEFV, the gene resposible for FMF, was identified on chromosome 16p13.3 via 
positional cloning (Fig. 1.1) [4,5]. MEFV spans 15 kb of this region and encodes an 
~3.7 kb transcript which is consist of 10 coding exons [6]. MEFV belongs to a highly 
conserved gene family comprising nuclear effector molecules and nucleic acid 
binding proteins which regulate oncogenesis, embryonic development, inflammation 
and hematopoiesis [7]. The gene is mainly expressed in neutrophils, eosinophils, 
monocytes, dendritic cells and synovial fibroblasts [3] that generates a protein of 781 
amino acids named pyrin[4] or marenostrin[5]. The expression of MEFV is increased 
by interferon γ (IFN-γ), tumor necrosis factor α (TNF-α), lipopolysaccharide (LPS) 
and interleukin 1β (IL-1β) which are proinflammatory agents [8]. 
 
 
 
 
 
    Figure 1.1: Schematic Representation of the MEFV Region on Chromosome 
16p13.3 [9]. 
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1.1.1 MEFV mutations and expression 
Until today, 246 sequence variations are identified on MEFV gene. 119 of these 
variations associated with FMF were defined (Fig. 1.2) [10]. Mutations are located in 
exons 1, 2, 3, 5, 9 and 10 of MEFV. Two mutational hot spots have been identified: 
one in exon 2 and one in exon 10 [11]. The five most common mutations are E148Q, 
which is located on exon 2 and M694V, M680I, M694I and V726A, which are 
located on exon 10 that corresponds to B30.2 domain of pyrin/marenostrin protein 
[12].  
Several gene expression studies have reported the association between MEFV 
mutations and MEFV expression levels. In a recent study that our group published, 
MEFV gene expression levels were lower in Turkish FMF patients compared with 
healthy controls. On the other hand, significant differences were not found between 
FMF patients with mutations and FMF patients without mutations [13]. 
 
 
                                      Figure 1.2 : MEFV mutations [11] 
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1.2 Alternative splicing and MEFV gene 
1.2.1  Alternative splicing 
Alternative splicing is a posttranscriptional regulatory mechanism that creates 
multiple transcripts from the same gene and potentially different protein isoforms, 
which contributes significantly to the diversity of cell and tissue specific protein 
expression profiles [14], in higher eukaryotes. It has been established that alternative 
splicing occurs in up to 95% of human multi-exon genes by recent studies [15,16]. 
Alternative splicing can lead to human disease if it is misregulated [17]. 
Alternative splicing events are grouped into six types: (1) casette-type alternative 
exons; (2) alternative selection of either 5’ or 3’ splice sites within the exon 
sequences; (3) mutually exclusive exons; (4) intron retention; (5) alternative 
promoters; (6) alternative polyadenylation (Fig. 1.3) [18]. In humans, the most 
frequent alternative splicing event is exon skipping [19,20].  
Predominantly, eukaryotic genes are interrupted by non-coding sequences which are 
called introns. RNA splicing excludes introns from the precursor mRNA (pre-
mRNA) and joins the exonic sequences to acquire mature functional mRNAs. The 
pre-mRNA splicing reaction, which is transcription-coupled or taken place post-
transcriptionally [21], is carried out by the spliceosome which is a RNA-protein 
complex containing small nuclear ribonucleoproteins (snRNPs) and a large number 
of accessory non-snRNP proteins [22]. 
Alternative splicing affects the production of protein isoforms indicating loss or gain 
of function and/or altered subcellular localization, posttranslational modifications, 
stability or enzymatic activity and also alters protein expression in the untranslated 
regions (UTRs) [23,24]. Furthermore, this mechanism frequently creates 
nonfunctional mRNAs including premature termination codons (PTCs), which 
causes mRNA down-regulation because of nonsense-mediated decay (NMD), an 
mRNA surveillance mechanism that prevents accumulation of truncated and 
potentially deleterious proteins [25]. 
Although MEFV is  generally transcribed into a major full-length transcript, its 
alternatively-spliced isoforms are revealed as well. MEFV gene has fourteen 
alternatively-spliced transcripts except full-lenght (fl) which are 2Δ (d2), 2a, 4a, 
8ext, 2Δ/4a, 2Δ/8ext, 2Δ/9ext, 2a/4a, 2a/8ext, del2.3.4, del2.3.4 del7, del2.3.4 del7.8, 
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Figure 1.3 : Different types of alternative splicing [18]. 
 
 
del2.3.4.5, del3.4 del7.8 (Fig. 1.4). 2Δ , which is the first described MEFV spliced-
isoform, is generated by in-frame alternative splicing of exon 2 and expressed in 
peripheral blood leukocytes (PBLs) [6]. Subsequently, more transcript isoforms that 
introduce various combinations of novel exons 2a and 4a, and a 3’ extension of exon 
8 (8ext) were identified in synovial fibroblasts [26]. Recently, detected six more 
weakly expressed transcripts were detected, with various deletions in exon 2, 3, 4, 7 
and 8, or a 5’extension of exon 9 (9ext) in PBLs. Among these MEFV alternative 
transcripts only seven transcripts can be translated to proteins: Fl, 2Δ, 2Δ/8ext, 
2Δ/9ext, 8ext, 2a, 2a/4a [27,28]. 
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Figure 1.4: Schematic representation of  currently known MEFV transcripts 
isoforms [29]. 
1.2.1.1 Effects of histone modifications on alternative splicing 
Nucleosomes are a complex form of DNA packaged by histones. Histones are 
proteins which package and organize DNA [30]. The reversible modification of 
histones and the positioning of nucleosomes along the chromatin template regulate 
transcription [31,32]. At the same time, nucleosome positioning and specific histone 
marks are significantly correlated with the intron/exon structure of genes and this 
reflects connections between chromatin and splicing [33]. 
Histones are assigned in innumerable post-translational modifications, and their N-
terminal tails are subjected to acetylation, methylation, phosphorylation, 
ubiquitylation or sumoylation [34]. These histone modifications are major splicing 
regulators. For instance, treatment with deacetylase inhibitors has been shown to 
affect the alternative splicing of several reporter and endogenous genes [35], and 
histone acetylation is important for co-transcriptional spliceosome assembly [36]. 
These data support a model in which histone modifications actively participate in the 
coupling of transcription and splicing. 
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1.2.1.2 Effects of DNA methylation on alternative splicing 
DNA methylation, the most common epigenetic mechanism, occurs at the cytosine 
bases in CpG islands present in the gene promoter. CpG islands are defined as the 
regions which CpG dinucleotides are contentrated in [37]. In addition to that, 
methylation of CpG islands at first and second exons cause also transcriptional 
silencing by preventing the RNA polymerase II transcription elongation [38]. 
DNA methylation has also been shown to be enriched in exonic regions, although it 
remains unknown how this modification affects the splicing outcome. Methylation 
could affect splicing in combination with other factors. For example, in the CD45 
gene, DNA methylation 
inhibits the inclusion of exon 5, and this methylation pattern opposes that of CTCF, 
which promotes the inclusion of exon 5 [39]. 
DNA methylation occurs in different regions of the genome and it has great 
importance in embryogenesis, cellular differentiation, and tissue-specific 
development. DNA methylation varies among tissues and cell type because it is a 
dynamic process involving methylation and demethylation events [40-42] and plays 
a role in normal regulatory functions.  
DNA methylation also may have a role on alternative splicing of MEFV gene 
including a CpG island which spans the complete second exon and a part of first 
intron. Our group have shown that methylation level of exon 2 is slightly higher in 
FMF patients compared with healty controls (P= 0,049) [13] and exon 2 deleted form 
in FMF patients is significantly higher compared to healty controls (P=0.026) [43], 
respectively which may indicate a possible connection between methylation and 
alternative splicing at this site. 
1.3 Pyrin/Marenostrin; the product of MEFV gene 
Pyrin is an 86-kDa protein described as the cause of FMF [44]. Pyrin contains five 
domains including a pyrin (PYD)  domain at the N-terminus, a bZIP transcription 
factor basic domain, a B box zinc finger domain, a coiled-coil domain, and a C-
terminal domain known as a B30.2 (PRYSPRY) domain (Fig. 1.5). These last three 
domains form  a tripartite motif, which is contained in proteins involved in viral 
recognition. Therefore, pyrin is also known as TRIM20 [45,46]. Each domain has a 
distinct role in the protein–protein interactions with proteins that are connected to 
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inflammation through cytokine secretion, transcriptional regulation, cytoskeletal 
signaling and regulation of cell death [8]. 
 
 
Figure 1.5: The structure of MEFV gene and its product, pyrin. (a) Structure 
of MEFV gene; exon 10, where the four most common mutations are 
located, is highlighted in red. (b) Domain organization of pyrin 
protein.PYD, pyrin domain; bZIP, bZIP transcription factor basic domain; 
BB, B-box domain; CC, coiled coil domain and B30.2, C-terminal B30.2 
domain [47]. 
 
N-terminal PYD, which is a member of the death domain family, promotes specific 
protein-protein interactions. The PYD of pyrin is believed to cooperate with other 
PYD-containing proteins within the inflammasome, which is a multi-protein 
complex activated on cellular infection or stress, triggers the maturation of 
proinflammatory cytokines such as IL-1β to engage innate immune defenses [48]. 
The PYD domain is found in more than 20 proteins involved in inflammation and 
apoptosis [49,50]. Proteins containing death domain motifs function to maintain the 
delicate balance between survival and death through regulation of nuclear factor 
(NF)- κB activities and caspase activation and, possibly, disruptions or imbalances in 
these pathways would result in autoinflammatory disorders and cancer [51]. 
The B-box zinc finger motif and the coiled coiled domain are involved in protein-
protein interactions. The C-terminal B30.2 domain is present in more than 700 
mammalian proteins. It is present in proteins that are involved in diverse functions 
such as cytokine signaling, RNA metabolism, intracellular calcium release, 
differentiation and immunity to viruses.[52-54] 
There are only few proteins that are known to interact with pyrin. Pyrin interacts with 
proteins which are involved in a variety of functions (Fig. 1.6). Pyrin specifically 
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interacts with apoptosis-associated speck-like protein (ASC), which is a 22-kDa 
adaptor protein, with a caspase-recruitment domain (CARD), through PYD domain. 
Wild-type pyrin, when overexpressed in HeLa cells, seems to increase ASC speck 
formation and, paradoxically, increase the survival of these cells. In addition to its 
role in apoptosis, ASC also nucleates inflammasome through its PYD domain and 
CARD with NLRP proteins and inflammatory caspases, respectively, thus activating 
IL-1β [55-60]. 
Pyrin seems to function as a negative regulator of ASC activity [51]. ASC has been 
shown to mediate the proteolytic activation of caspase-1 and plays an important role 
in regulating cytokine secretion, NF-jB activation, and apoptosis [50, 61-65]. 
As pyrin binding partners, 14.3.3τ and 14.3.3ε proteins which control intracellular 
signaling, cell-cycle control and apoptosis. This pyrin-14.3.3 interaction modulates 
the localization of pyrin in the cell. Pyrin-14.3.3 interaction is required for 
cytoplasmic localization of pyrin. Pyrin interacts with 14.3.3τ and 14.3.3ε through 
exon 2. A alternate spliced form of pyrin which lacks exon 2, is unable to interact 
with pyrin and this alternatively spliced form of pyrin is located in nucleus. This 
interaction is also dependent on the phosphorylation state of exon 2 [66]. 
~ 200-residue C-terminal B30.2 domain of pyrin is where most of the FMF-causing 
mutations are situated. Its role in inflammation seems likely that pyrin modulates 
caspase-1 activation through binding of its C-terminal B30.2 domain to the catalytic 
domains of caspase-1 and it binds to procaspase-1. Moreover, the B30.2 domain of 
pyrin also interacts with pro-IL-1β, and this interaction contributes additional 
blockade of IL-1β secretion [67-71].  Having mutations in this domain in individuals 
with FMF leads to less IL-1β activation and higher IL-1β responsiveness, resulting in 
increased inflammatory attacks. Higher IL-1β responsiveness may also be one of the 
factors selecting for pyrin mutations, giving a genetic advantage[70]. 
Pyrin is involved in interacting with a proapoptotic protein siva-1. This interaction of 
pyrin with siva-1 modulates recruitment of siva-1 to the ASC specks and thereby 
apoptosis induced by oxidative stress [72].  
Pyrin also co-localizes with actin and it interacts with microtubules [56], suggesting 
a rationale for the current highly efficacious treatment of the disease with colchicine, 
a microtubule-destabilizing agent [57]. 
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Figure 1.6: Interacting partners of pyrin protein [73]. 
 
Pyrin interacts with ASC through the N-terminal pyrin domain. As ASC is involved 
in both NF-κB activation and caspase-1 activation, we can speculate that pyrin may 
have role in ASC mediated caspase-1 activation and NF-κB activation 
[50,61,64,74,75]. Pyrin is cleaved by caspase-1, which is involved in proteolytic 
processing and activation of proinflammatory cytokines; pro-IL-1 and pro-IL-18, 
between bZIP and B-box domain and the N-terminal cleaved fragment localizes to 
the nucleus and potentiates NF-κB activation. NF-kB is a protein complex that 
regulates the immune response of the cell. The exact role of pyrin in NF-κB 
activation is not clear yet. Hovewer Pyrin may enhance NF-κB activity in two 
possible ways, assisting the entrance of p65 NF-kB into nucleus and enhancing the 
degradation of inhibitor of NF-κB (IkB)-a [70,76]. The interaction of N-terminal 
cleaved pyrin with IkB-a  induces the degradation of IkB-a, which is also different 
from the classical NF-κB activation pathway [8]. PYD domain can also bind 
indirectly to the IkB kinase (IKK) complex, affecting activation of NF-κB [76-78].  
Both activating and suppressing effect of pyrin has been reported. There are two 
hypotheses regarding the function of pyrin. One is the sequestration hypothesis, in 
which pyrin takes away ASC and caspase-1 which are needed for the inflammasome 
formation by sequestering ASC and caspase-1 molecules. In support of sequestration 
hypothesis, it has been demonstrated that pyrin blocks IL-1β processing at two 
levels. Pyrin blocks the function of ASC by binding ASC through the N-terminal 
pyrin domain and also blocks the caspase-1 activation by binding to procaspase-1 
molecule. Thus, pyrin is believed to be a negative regulator of inflammation because 
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it blocks caspase-1 activation and thereby IL-1β processing and release [79]. The 
other hypothesis is the inflammasome hypothesis which indicates that pyrin might be 
an activator of caspase-1 by forming the pyrin inflammasome in which the B30.2 
domain of pyrin may be involved in pathogen recognition (Fig. 1.7) [58]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   Figure 1.7: Proposed role of pyrin in regulating of inflammation[79]. 
 
1.3.1 Protein localization and Pyrin/Marenostrin localization studies 
1.3.1.1 Protein localization 
The translocation of proteins between the cytoplasm and the nucleus is an essential 
requirement to maintain cell homeostasis [80]. The regulation of protein trafficking 
is carried out by two major mechanisms, namely co-translational and post-
translational translocation (i.e. proteins targeted to the nucleus). Synthesized proteins 
are delivered to their target destinations where they function through the information 
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that is encoded within the protein sequence [81-83]. Nuclear proteins, including 
structural proteins, transcription factors and other functional proteins must be 
delivered into the nucleus after their synthesis in the cytoplasm unlike cytoplasmic 
proteins. The proteins that pass through nuclear pores contain a nuclear localization 
signal (NLS) and a nuclear export signal (NES) within their primary structure. 
Transport factors recognize and transport cargo proteins containing these signals 
through the nuclear pore [84]. 
Subcellular localization designates the access of proteins to interacting partners and 
the post-translational modification machinery. Abnormal localization of proteins 
partakes to the pathogenesis of many human diseases, such as metabolic, 
cardiovascular and neurodegenerative diseases. This localization event of disease-
related proteins can be influenced by binding to other biomolecules and by 
posttranslational modification, including phosphorylation, acetylation, ubiquitylation 
and proteolytic processing [85]. 
1.3.1.2 Pyrin/Marenostrin localization studies 
 
First localization study demonstrated that green fluorescent protein (GFP)-tagged 
pyrin was expressed in the cytoplasm of transfected COS-1 (fibroblast-like cell 
line derived from monkey kidney tissue) cells [86]. Latter study reported that Pyrin-fl 
was homogeneously distributed over the entire cytoplasm, whereas pyrin-2Δ 
concentrated into the nucleus in stably transfected CHO (Chinese hamster ovary) cell 
lines [6]. In subsequent study, the localization of normal/mutated full-length and 2Δ-
pyrin were compared with each other in HeLa cell lines. However most frequent 
MEFV mutations did not affect the localization of two pyrin forms. Likewise, full-
length pyrin was located in the cytoplasm and 2Δ form was located in the nucleus. 
Pyrin-fl with ASC was also co-expressed, it resulted in formation of aggregates, 
termed specks, in which both proteins colocalise. Mutated M/P-fl protein with ASC 
resulted in the formation of specks also in which the two proteins colocalised. And 
when wild type or mutated M/P-d2 isoforms were expressed with ASC, Similar 
cytoplasmic specks were observed [87]. The  latest study indicated that myc-tagged 
full-length pyrin was cytoplasmic, but myc-tagged 2Δ was not exclusively nuclear 
and were more often cytoplasmic in synovial fibroblasts, suggesting that it may 
shuttle between cytoplasm and nucleus. Nonetheless, native pyrin, which consists of 
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predominantly pyrin-fl, was nuclear in synovial fibroblasts, neutrophils, and 
dendritic cells, but was cytoplasmic in monocytes [26]. 
1.4 HL-60 cell line and differentiation studies 
 
The HL-60 cell line was derived from peripheral blood leukocytes of a 36-year-old 
Caucasian female with acute promyelocytic leukemia. It was the first long-term 
suspension cultures of human myeloid leukemic cells to be established. The wild-
type HL-60 cell line has several properties of malignant cells and expresses various 
oncogenes [88]. It is able to grow as colonies in semisolid medium (methylcellulose 
and agar), which could be enhanced with various colony-stimulating factors and with 
increasing passage.  
HL-60 cells can be differentiated into neutrophil-like, monocyte-like or macrophages 
depending on the differentiation method used. Inducers such as retinoic acid, 
dimethyl sulfoxide (DMSO) is reported to induce granulocytic differentiation, 1-α, 
25-dihydroxivitamin D3 induces monocytic differentiation [89] and phorbol esters 
differentiates to macrophages. Optimized conditions have been described by various 
authors for differentiation into neutrophils and these include 1.25% (vol/vol) of 
DMSO in a period of 5 to 7 days, 100 mM DMF in a period of 5 days, or 0.1 uM all-
trans-retinoic acid (ATRA) in a period of 5 days [90]. 
In culture, HL-60cells are round but occasionally express pseudopods and are 
heterogeneous in size (9 to 25 um in diameter). HL-60 cells have large round nuclei 
and two to four nucleoli. The cytoplasm is deeply basophilic with prominent multiple 
azurophilic granules [91,92]. Neutrophil-like cells (10-16um), which is differentiated 
from HL-60 through DMSO, have horseshoe-shaped or segmented nuclei. The 
cytoplasm includes many small, distributed light pink granules (Fig. 1.8) [93]. 
As HL-60 cells differentiate; they cease proliferation, begin to express new genes 
and molecules, undergo morphological changes, and then die by apoptosis [94]. Such 
changes can be monitored by microscopic, flow cytometric, and molecular 
techniques. Morphological changes during differentiation containing shrinkage in 
cell size, increased nuclear pyknosis and segmentation, decreased nuclear-
cytoplasmic ratio, decreased cytoplasmic basophilia, replacement of the coarse 
azurophilic granules with smaller specific granules [88], and alterations in gene and 
protein expression along macrophage and granulocytic lineages[95,96]. 
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Figure 1.8: Morphology of neutrophil [97] and HL-60 [98], respectively. 
                
1.5 Aim of the study 
The aim of this study was to investigate subcellular localization differences between 
pyrin-fl and pyrin-2Δ, which are products of MEFV gene associated with FMF 
disease, in neutrophil-like cells. Therefore, HL-60 cells differentiated to neutrophil-
like cells via exposure of DMSO first and then each of GFP-tagged plasmids, which 
contain two pyrin isoform, transfected to HL-60 cells and neutrophil-like cells both. 
Ultimately, localization of pyrin isoforms were examined through confocal 
microscopy and compared with each other. 
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2.  MATERIALS and METHODS 
2.1 Materials and laboratory equipment 
2.1.1 Used equipments 
The laboratory equipment used in this study is listed in Appendix A. 
2.1.2 Used chemicals, enzymes, markers, commercial kits and plasmid maps 
The chemicals, enzymes, markers and commercial kits used are given in Appendix B 
with their suppliers. The compositions and preparation of buffers and solutions are 
given in Appendix C. Used plasmid maps and their suppliers are given in Appendix 
D. 
2.2 Amplification of the exon 2-deleted transcript of MEFV (MEFV 2Δ) from 
PTZ57R/T vector  
The exon 2 spliced transcript of MEFV gene, was obtained from previously cloned in 
the PTZ57R/T vector construct, was used as template for PCR reaction. Touch down 
PCR was used to increase the stringency of the hybridization. 
 
                                  Table 2.1 : PCR mix for PCR amplification 
Ingredients Final Concentration Reaction mixture (20µl) 
10X Taq Buffer 1X 4µl 
10mM dNTP 0.25mM 1µl 
25mM MgCl2 1.5mM 2µl 
20mM Forward Primer 1µM 1µl 
20mM Reverse Primer 1µM 1µl 
Sterile dH2O - 6.6µl 
DNA - 2 µl 
Betain - 2µl 
Taq DNA polymerase 5u/µl 0.4µl 
 
 
The sequence of the forward primer used was 5’-GCA AGA TCT ATG GCT AAG 
ACC CCT AGT GAC C-3’, containing a Bgl II restriction site (underlined). 
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The sequence of the reverse primer used was 5’-GCA CTC GAG TAG CAC CTA 
GTC GGC-3’, containing a Xho I restriction site (underlined). 
 
Table 2.2 : Touch-down PCR condition 
Initial Denaturation 95oC 5 min  
Denaturation 95oC 30 sec 
Annealing 68-52oC 30 sec 
Extension 72oC 2 min 
 
X 33 
Final Extension 72oC 10 min  
                                   
1% agarose gel was used for observation of PCR product (1700 kb). The gel was run 
and monitored under UV light. 
2.3 Agarose gel electrophoresis 
 
For the observation of the pcr product which is 1.7 kb, 1% agarose gel is sufficient.  
The agarose gels contain 0.5 g agarose dissolved in 50 mL of 1X TAE buffer as well 
as 0.5µg/mL ethidium bromide. To evaluate the length of the pcr product, marker 
was loaded into the first wells of the gels. 5 µL of the product were mixed with 1 µL 
of 6X loading dye to faciliate the precipitation and the observation of relative 
position with naked eye. The gel were run for an average of 25-30 minutes in 100V 
into 1X TAE buffer. The results were monitored via transilluminator under UV light. 
2.4 Gel extraction 
 
The Roche High Pure PCR Product Purification Kit was used for the DNA 
extraction. 
1. After the electrophoresis process, the gel was observed under UV 
illumination.  The desired DNA band were excised from the gel using an 
ethanol-cleaned scalpel and placed in 1,5ml pre-weighed microcentrifuge 
tubes.  
2. The weight of gel slice were determined by re-weighting the tubes with the 
excised gel slices. 
3. 300 µl Binding Buffer for 100 mg agarose gel slice was added to the 
microcentrifuge tube. 
4. Agarose gel slice was dissolved in order to release the DNA and the 
microcentrifuge tubes were vortexed for 15 - 30 seconds to resuspend the gel 
slice in the Binding Buffer.  
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5. The suspension was incubated for 10 minutes at 56°C. The tubes briefly 
vortexed every 2 - 3 minutes during incubation. 
6. After the agarose gel slice was completely dissolved, 150 µl isopropanol for 
every 100 mg agarose gel slice was added to the tube and vortexed 
thoroughly. 
7. One column was inserted into one collection tube. The entire contents of the 
microcentrifuge tube was pipetted into the upper reservoir  of the column. 
8. The tube was centrifuged 30 - 60 seconds at maximum speed in a standard 
table top centrifuge at +15 to +25°C. The flowthrough solution was 
discarded. 
9. 500 µl Wash Buffer was added to the upper reservoir and the tube was 
centrifuged for 1 minute at maximum speed. The flowthrough solution was 
discarded. 
10. 200  µl Wash Buffer was added to ensure optimal purity and complete 
removal of Wash Buffer from the glass fibers and the tube was centrifuged 
for 1 minute at maximum speed. 
11. The flowthrough solution and collection tube were discarded. The column 
was recombined with a clean 1.5 ml microcentrifuge tube.  
12. 30µl Elution Buffer was added to the upper reservoir of the column and the 
tube centrifuged for 1 minute at maximum speed. 
13. The eluted DNA was stored at – 20°C for later analysis. 
2.5 pCMV-myc subcloning procedures 
2.5.1 Restriction digestion of the PCR products 
 
PCR product of MEFV 2Δ was blunt ended  and it should be having cohesive ends 
for the successful ligation. Thus, it  was digested with the Bgl II and Xho I enzymes 
according to the protocol showed in Table 2.3. 
According to the restriction enzyme digestion protocol, the PCR product were left 
overnight with the enzyme mix at 37 °C for efficient digestion. An additional step at 
80 °C for 20 minutes was needed for the inactivation of the enzyme leading to 
digestion arrest.  
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Table 2.3 : Restriction Enzyme Digestion mixture for the PCR products 
Ingredient     1X amount 
10X Buffer Tango 2 µL 
dH2O 3 µL 
Bgl II (10 U/ µL) 1 µL 
Xho I (10 U/ µL) 2 µL 
Amplicon 12 µL 
Final Volume 20 µL 
 
2.5.2 Restriction digestion of the pCMV-myc vector 
pCMV-myc vector (3.8 kb) was digested by using same restriction enzymes. 
 
      Table 2.4 : Restriction Enzyme Digestion mixture for the pCMV-myc vector. 
Ingredient     1X amount 
10X Buffer Tango 2 µL 
dH2O Variable 
Bgl II (10 U/ µL) 1 µL 
Xho I (10 U/ µL) 2 µL 
Amplicon (up to 1 µg) Variable 
Final Volume 20 µL 
 
2.5.3 Ligation of the PCR product and the pCMV-myc vector 
 
Ligation of the digested pcr product into the digested pCMV-myc vector was 
performed using the Roche Rapid DNA Dephos & Ligation Kit. 
 
1. The following reagents were added to a reaction tube: 
 
Table 2.5 : Dephosphorylation mixture for vector DNA. 
Reagent Volume Final Concentration 
Vector DNA 5µl Up to 1µg 
10X Alkaline Phosphatase 
Buffer 
2µl 1X 
Alkaline Phosphatase 1µl 1 U 
dH2O 12µl  
Total volume 20µl  
 19 
2. All reagents were mixed thoroughly and centrifuged briefly. The tube was 
incubated for 30 min at +37°C. 
3. Then the Alkaline Phosphatase was inactivated for 2 min at +75°C. This 
dephosphorylation reaction mixture was used for ligation step. 
Table 2.6 :  Ligation mixture. 
Reagent Volume Final Concentration 
Vector DNA (from above 
mixture) 
1 µl 50 ng 
Insert DNA 5 µl 150 ng 
5X DNA Dilution Buffer 2 µl 1X 
dH2O 2 µl  
Total volume 10 µl  
Mix thoroughly 
2X T4 DNA Ligation 
Buffer 
10 µl 1X 
T4 DNA Ligase 1 µl 5 U 
 
4. Ligation mixture was incubated for 5 min at room temperature. 
2.6 Competent E.Coli Top10 strain preparation 
 
1. 10 µl of overnight E. coli Top 10 culture was transferred to 100 ml LB broth. The 
culture was incubated for 1 hour shaking at 250 rpm.  
2. All ependorfs, falcon tubes to be used and the CaCl2 solution were prechilled on 
ice.  
3. 100 ml culture was transferred to two sterile ice-cold 50 ml falcon tubes.  
4. The cultures were cooled to 0oC by incubating the tubes on ice for 10 minutes.  
5. The cells were recovered by centrifugation at 3000 rpm for 7 minutes at 4oC.  
6. The supernatant was discarded and 10 ml ice-cold CaCl2 was added to each tube. 
The pellet was gently resuspended by vortexing. 
7. Another centrifugation was performed at 2500 rpm for 5 minutes at 4oC.  
8. The supernatant was discarded again and 10 ml ice-cold CaCl2 was added to each 
tube. The pellet was gently resuspended by vortexing.  
9. The samples were incubated on ice for 30 minutes.  
10. A third centrifugation step was performed at 2500 rpm for 5 minutes at 4oC.  
11. The bacterial cells were recovered and 2 ml ice-cold CaCl2 was added to each 
tube and the pellet was gently resuspended.  
12. The bacterial cells were transferred to cooled microcentrifuge tubes in 40 µl 
aliquots and kept at – 80oC.  
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2.7 Transformation 
 
Heat-shock transformation method was performed. 
1. Competent E.Coli cells (Top10 strain) were taken from -80ºC and thawed on 
ice. All ependorf tubes were also cooled on ice.  
2. 40 µl competent cells and 4 µl pCMV-myc plasmid containing the MEFV 2Δ 
isoform transcript were mixed in a 1,5 ml ependorf tube. The mixture was 
cooled on ice for 30 minutes. 
3. The tube was transferred to a water bath at 42oC for 45 seconds.  
4. Then, the tubes were placed immediately on ice for 2 minutes.  
5. 250 µl SOC medium was added to each tube and the cells were incubated at 
37oC shaking at 220 rpm for 1 hour.  
6. 5, 10 and 20 µl of each sample were spread on appropriate LB plates. All 
plates were incubated at 37oC overnight (12-16 hours, no more than 20 
hours). 
2.8 Colony PCR 
DNA sample for colony PCR was taken by touching the tip of a sterile micropipette 
to a selected colony. The tip was incubated in a PCR tube containing 10µl of dH2O 
for 5 minutes. Then the tubes were heated at 85oC for 15 min for the lysis of cells 
and 10µl PCR mix was added to each sample. Colonies giving a positive result in 
colony PCR were chosen for the overnight culture at 37oC shaking at 250 rpm in 10 
ml LB broth containing 100 µg/ml ampicillin. Plasmid isolation was done from these 
cultures. 
 
Table 2.7 : PCR mix for colony PCR. 
Ingredients Final Concentration Reaction mixture (10µl) 
10X Taq Buffer 1X 2µl 
10mM dNTP 0.25mM 0.5µl 
25mM MgCl2 1.5mM 1µl 
20mM Forward Primer 1µM 0.5µl 
20mM Reverse Primer 1µM 0.5µl 
Sterile dH2O - 4.3µl 
Betain - 1µl 
Taq DNA polymerase 5u/µl 0.2µl 
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2.9 Plasmid isolation 
 
Plasmid isolation, from positive colonies grown overnight, was made using the 
Roche High Pure Plasmid Isolation Kit. 
1. 5 ml overnight culture was centrifuged at 6000 x g for 30 seconds. 
2. The bacterial pellet was resuspended in 250µl Suspension Buffer + RNase and 
mixed well. 
3. 250µl Lysis Buffer was added, mixed gently by inverting the tube 3 to 6 times and 
incubated for 5 minutes at 15 oC - 25 oC 
4. 350µl chilled Binding Buffer was added, mixed gently by inverting the tube 3 to 6 
times and incubated on ice for 5 minutes. 
5. The tube was centrifuged for 10 minutes at approx. 13000 x g. 
6. Entire supernatant was transferred to column provided by the kit and centrifuged 
for 1 minute at full speed and discard the flowthrough liquid. 
8. 700µl Wash Buffer II was added to the column and centrifuge for 30-60 seconds at 
full speed. 
9. The flowthrough liquid was discarded and the tube was centrifuged for additional 
1 minute to remove residual Wash Buffer. 
10. The column was inserted into a clean, sterile microcentrifuge tube and 30µl 
Elution Buffer was added. 
11. After waiting for 1 hour, the sample was centrifuged at full speed for 1 minute. 
12. The column was discarded and the eluted DNA was stored at -20oC. 
2.10 DNA sequencing 
After plasmid isolation of pCMV-myc + MEFV 2Δ, restriction digestion was 
performed for this construct with the same protocol described before to verify the 
sequence of insert via DNA sequencing. Digested fragment was visualized by gel 
electrophoresis and insert was purified from gel for sending to Refgen, Ankara for 
sequence analysis. 
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2.11 Cell culture and differention assay 
2.11.1  Preparation of cell culture  
HL-60 cells were supplied by DETAE. HL-60 cells were grown in liquid suspension 
in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml 
penicilin, 100 µg/ml streptomycin. The cells were cultured at 37°C in a humidified 
atmosphere containing 5% CO2.  
2.11.1.1 Transferring the stock cell to culture flask  
A frozen stock of HL-60 cells were taken from nitrogen tank and after the cells were 
thawed in 37oC water bath. They were diluted with HL-60 culture medium, and 
centrifuged for 5 min at 1000 rpm. Cell pellet was dissolved with medium and 
transferred to the culture flasks. 
2.11.1.2 Counting and determining the viability of cultured cells 
Cell number was determined in a hemocytometer chamber and cell viability was 
determined by trypan blue dye exclusion. 10 µL  was taken from suspension culture 
and cells were exposed to Trypan blue dye (2 µL). Dual-chamber FisherLab 
hemacytometer was filled with 10 µL of cells from trypan blue-medium mixture and 
cells were counted under a light microscope, non-viable cells were observed as 
stained while viable cells excluded the stain. 
The cell number calculation is as follows:  
104 (constant number) x Amount of counted cell = Cell number/ml  
Total cell number = Cell number/ mL x Total volume of cells  
2.11.1.3 Cell passage  
Cell density was determined, cells were put into the centrifuge tubes and centrifuged 
1000 rpm for 5 min. The supernatant was discarded and pellet was resuspended with 
culture medium and 1x106 cells were transferred to clean culture flask. Cell passage 
was made once a month. Cell cultures were diluted with fresh medium every 48 
hours instead of passaging. 
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2.11.1.4 Cell freezing 
Cell density was determined and 1x106 cells per vial were centrifuged 1000 rpm for 
5 min. The supernatant was discarded and pellet was resuspended with culture 
medium and 10% DMSO Then they were transferred to vials for future experiments. 
2.11.2 Differentiation assay and imaging 
Cells were induced to differentiate to neutrophils with 1,75 % (vol/vol) DMSO for 6 
days. 2x105 cells/mL, 1.5x105 cells/mL, 1x105 cells/mL and 0.5x105 cells/mL were 
used as initial cell numbers. Cell cultures were diluted with fresh medium every 48 
hours, and chemical concentrations were adjusted accordingly. Differentiated cells 
were imaged by using procedure below: 
1. Coverslips (13 mm circles) were cleaned with ethanol and coverslips and 12-
well plates steriliazed by UV.  
2. Poly-L-Lysine (PLL) was diluted from 1mg/mL stock solution with sterile 
dH2O to 200µg/mL.  
3. Each of coverslips were covered with PLL solution and left for 1 hour at 
room tempature. Then coverslips were washed with sterile dH2O three or four 
times and they were allowed to air dry. 
4. The required number of cells (5 x 105 cells per sample) was centrifuged at 
90xg for 10 minutes at room temperature and supernatant was removed 
completely. 
5.  Cells were resuspended with medium and was transferred on coverslips 
covered with PLL. 
6. The cells were incubated in humidified 37°C/5% CO2 incubator 24 hours. 
7. After 24 hours, medium was removed and cells were rinsed with Phosphate 
Buffered Saline (PBS). 
8. 1mL pre-cold (-20°C) methanol was added into the wells and plate was stored 
at -20°C for 15 minutes for fixation.  
9. Methanol was removed and cells were washed briefly three times with PBS. 
10. DAPI was diluted 1:1000 with PBS from 0,3mM stock solution. 1mL DAPI 
was added onto coverslips and incubated for 1 minute.  
11. Cells were rinsed 3 times with PBS for 5 minutes and dried coverslips were 
inverted onto microscope slides with 15 µL mounting media. Around the 
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coverslips were sealed with regular transparent nail polish and allowed to dry 
for 3 minutes.  
12. Cells were visualized using a confocal microscope. 
2.11.3 Flow cytometry assay 
Differentiation rate of HL-60 cells were determined through flow cytometry by using 
PE-CD44 antibody: 
 
1. Cell numbers of HL-60 and DMSO-treated HL-60 (dHL-60) were determined 
in a hemocytometer chamber and the required number of cells (2.4 x 105 cells 
per sample) was centrifuged at 1780 rpm for 8 minutes at room temperature 
and supernatant was removed completely. 
2. Each pellet was dissolved in 200uL cold PBS containing 2% FBS (FACS 
buffer). 
3. Each of cell suspension was split in two tubes, separately. One tube was for 
unstained control and the other one was for CD44 staining. 
4. Unstained HL-60 and dHL-60 were analyzed via flow cytometry. 
5. 15uL PE-CD44 antibody was added to other tubes of HL-60 and dHL-60 and 
incubated for 40 minutes on ice. 
6. After incubation, cells were washed with 1mL cold FACS buffer and 
centrifuged at 3000 rpm for 7 minutes. 
7. Cell pellets were dissolved in 200uL FACS buffer and analyzed via flow 
cytometry. 
2.12 Transient transfection and imaging of protein localization 
2.12.1 Transfection 
MEFV-d2-myc was transfected to HL-60 cells. Lonza Amaxa Nucleofection Kit was 
used for transfection assay. 
Table 2.8 : Nucleofection mixture. 
Cells 2 x 106 
Plasmid DNA 5 µg 
Nucleofector Solution+Supplement 
(4.5:1) 
100 µl 
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1. Coverslips were prepared and covered with PLL as mentioned before. 
2. Each of coverslips were covered with PLL solution and left for 1 hour at 
room tempature. Then coverslips were washed with sterile dH2O three or four 
times and they were allowed to air dry.  
3. All of the coverslips were placed into wells. An aliquot of the cells was 
counted and cell density was determined. 
4. The required number of cells (2 x 106 cells per sample) was centrifuged at 
90xg for 10 minutes at room temperature and supernatant was removed 
completely. 
5. The cell pellet was resuspended carefully in 100 µl room-temperature 
Nucleofector Solution per sample (The cells should not be left in 
Nucleofector Solution longer than 15 minutes). 
6. 100 µl of cell suspension was combined with 5 µg DNA. 
7. Cell/DNA suspension was transferred into certified cuvette (sample must 
cover the bottom of the cuvette without air bubbles) and close the cuvette 
with the cap. 
8. The appropriate Nucleofector Program X-001(X-01 for Nucleofector® I 
Device) was selected. 
9. The cuvette with cell/DNA suspension was inserted into the Nucleofector 
Cuvette Holder and the selected program was applied. 
10. The cuvette was taken out of the holder once the program was finished. 
11. ~50 µl of the pre-equilibrated culture medium was added to the cuvette 
immediately and the sample was transferred on coverslips covered with PLL 
gently. 
12. The cells were incubated in humidified 37°C/5% CO2 incubator for 24 hours.  
2.12.2 Fluorescent staining and imaging protein localization 
DAPI was used for determination of cell nucleus. The blue-fluorescent DAPI nucleic 
acid stain preferentially stains dsDNA; it appears to associate with AT clusters in the 
minor groove. Binding of DAPI to dsDNA produces a ~20-fold fluorescence 
enhancement, apparently due to the displacement of water molecules from both 
DAPI and the minor groove.  
1. 24 hours after transfection, cells were fixed as mentioned above  
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2. Cells were blocked for 1 hour with 1% bovine serum albumin, 10% goat 
serum in PBS–0.1% Tween.  
3. Primary (Mouse monoclonal IgG anti-myc) and secondary antibodies (Goat 
anti-mouse Alexa Fluor  488 – conjugated polyclonal IgG) were also diluted 
with this blocking buffer.  
4. Firstly, cells were incubated with the diluted primary antibody for 1 hour at 
room temperature, then primary antibody was removed, cells were washed 
with PBS and incubated with secondary antibody for another 1 hour.  
5. Secondary antibody was removed and cells were washed with PBS.  
6. DAPI was diluted 1:1000 with PBS from 0,3mM stock solution. 1mL DAPI 
was added onto coverslips and incubated for 1 minute.  
7. Cells were rinsed 3 times with PBS for 5 minutes and dried coverslips were 
inverted onto microscope slides with 15 µL mounting media. Around the 
coverslips were sealed with regular transparent nail polish and allowed to dry 
for 3 minutes.  
8. Cells were visualized using a confocal microscope. Images were examined 
via Adobe Photoshop Programme. 
2.13 Plasmid constructs 
Used constructs, which are pCMV6-AC-GFP + MEFV-fl and pCMV6-AC-GFP + 
MEFV-d2, were obtained from Origene Technologies, Inc. Transformation was done 
and plasmids were isolated. To check GFP-tagged constructs with MEFV full length 
and MEFV 2Δ are digested with the Xho I enzymes according to the following 
protocol: 
 
Table 2.9 : Restriction Enzyme Digestion mixture for the plasmids. 
Ingredient     1X amount 
10X Buffer Tango 2 µL 
dH2O 3 µL 
Xho I (10 U/ µL) 1 µL 
Amplicon 14 µL 
Final Volume 20 µL 
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According to the restriction enzyme digestion protocol, the plasmids were left 4 
hours with the enzyme mix at 37 °C for efficient digestion. An additional step at 80 
°C for 20 minutes was needed for the inactivation of the enzyme leading to digestion 
arrest. Digested constructs were run on 1% agarose gel and monitored under UV 
light. MEFV-fl-GFP and MEFV-d2-GFP were transfected to HL-60 cells and 
neutrophil-like cells. Cells were visualized using a confocal microscope. Images 
were examined via Adobe Photoshop Programme. 
2.14 Total, cytoplasmic and nuclear protein isolation  
MEFV-fl-GFP and MEFV-d2-GFP were transfected to HL-60 cells and neutrophil-
like cells. Total protein isolation from HL-60 cells and neutrophil-like cells was 
performed by using Roche, complete Lysis-M Kit EDTA-free. All centrifugation 
steps were performed at 4°C: 
1. After 24 hours, one complete-M Mini tablet was dissolved in 1,5 mL 
ProteoJET Mammalian Cell Lysis Reagent Reagent to prepare working 
solution.  
2. Cells were centrifuged at 500g for 5 min. Culture medium was removed, and 
cells were washed with PBS. Cells were centrifuged again at 1000g for 2 min. 
3. 20 µL lysis buffer was added to each microcentrifuge tube and incubated for 
15 min on ice on an orbital shaker.  
4. Microcentrifuge tubes were cemtrifuged at 16000g for 15 min., and 
supernatants containing soluable proteins were transfered into clean tubes and 
stored -80°C. 
Cytoplasmic and nuclear protein isolation from HL-60 cells and neutrophil-like cells 
was performed by using Thermo Scientific, NE-PER Nuclear and Cytoplasmic 
Extraction Reagents. All centrifugation steps were performed at 4°C: 
1. Protease inhibitors were added to CERI and NER solutions, first. 
2. Cells were centrifuged at 500g for 5 min. Culture medium was removed, and 
cells were washed with PBS. Cells were centrifuged again at 500g for 2-3 
minutes. 
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3. Ice-cold CERI, using indicated volume in kit’s manual was added to the cell 
pellets. 
4. Tubes were vortexed for 15 seconds to suspend the cell pellets and were 
incubated on ice for 10 minutes. 
5. Ice-cold CERII was added to the tubes and tubes were vortexed for 5 seconds 
and were incubated on ice for 1 minute. 
6. Tubes were vortexed after incubation for 5 seconds and were centrifuged at 
16000g for 5 minutes. 
7. The supernatants containing cytoplasmic proteins were transfered into clean 
pre-chilled tubes and stored -80°C. 
8. The pellets which contain nuclei were suspended in ice-cold NER and the 
tubes were vortexed for 15 seconds. 
9. The tubes were incubated on ice for 40 minutes and vortexed for 15 seconds 
every 10 minutes during incubation. 
10. The tubes were centrifuged at 16000g for 10 minutes. 
11. The supernatants containing nuclear proteins were transfered into clean pre-
chilled tubes and stored -80°C. 
2.15 Bradford assay 
The determination of proteins was performed using Biorad’s Quick Start Bradford 
protein assay. The Bradford dye was diluted with distile water at 1:4 ratio. Bovine 
Serum Albumin Standard Set was chosen for microassay. 1X Bradford dye reagent 
was removed from the 4°C storage, and was warmed to ambient temperature. 200 µL 
of dye was shared each well in the plate, and all loading process was duplicated to 
confirm lineer range of standarts and to get more accurate results. 5 µL of BSA 
standarts were put into dye-loaded wells with the concentrations of 0,125; 0,25; 0,5; 
1; 1,5; 2 mg/mL, respectively. 5 µL of proteins of which concentrations were 
unkown were put into dye-loaded wells, and microplate was incubated at room 
temparature about 5 min. After incubation absorbance was measured at 595 nm on 
plate reader. 
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2.16 SDS-polyacrylamide gel electrophoresis of proteins (SDS-PAGE) 
Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis is a technique 
widely used to separate proteins according to electrophoretic mobility. The proteins 
are separated in gel according to their size. In this study, 5% stacking gel and 10 % 
separating gel were used. Prepared gels were poured between SDS-glasses and left 
for polymerization. After gel polymerized, samples, that were mixed 6X SDS-
loading dye and boiled 95°C for 5 min to gain primary structure, were loaded in 
equal concentration into wells. The gel was placed into a tank and was run in a 
running buffer at 25 mA for 2 h. 
 2.17 Western blotting 
Western blot is used to detect specific proteins. After SDS-PAGE, gel was taken 
from the tank and stripped off the glasses. Transfer of proteins from gel to the 
nitrocellulose membrane was done by using Trans-Blot Turbo transfer system; gel 
was put into Trans-Blot® Turbo Midi Nitrocellulose Transfer Packs, then protein 
transfer was carried out in Trans-Blot® Turbo tranfer system at 25 V for 10 min. 
After transfer, membrane was blocked with a blocking solution (BSA) for 1 hour to 
prevent non-specific binding to empty regions on the membrane. After blocking, the 
membrane was incubated with 1:500 and 1:1000 diluted with blocking solution (5% 
BSA in TBS-T) primary antibodies, which are listed in Appendix B, for overnight at 
4 °C with gentle shaking. Following day, membrane was washed with TBS-T buffer 
3 times for total 25 minutes with gentle shaking, 1:5000 diluted secondary antibody 
was prepared in blocking solution, and was incubated with secondary antibody for 1 
hour at room temperature. After 3 times washing of membrane with TBS-T, 20X 
LumiGLO® Reagent was used for the detection of proteins according to 
manufacturer’s instructions. The membrane was exposed to X-ray film for a certain 
time and then developed in Kodak Medical X-ray Processor according to 
manufacturer’s instruction. 
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3.  RESULTS  
3.1 PCR result of MEFV exon 2-deleted transcript 
The exon 2 spliced transcript of MEFV gene, was obtained from previously cloned in 
the PTZ57R/T vector construct via touch-down PCR (Fig. 3.1). 
 
Figure 3.1 : PCR product of MEFV-d2 isoform (M: Marker, Lane 1: MEFV-d2). 
 
3.2 Result of cloning MEFV-d2 to pCMV-myc vector 
Pcr product was purified and it and pCMC-myc vector were digested restriction 
enzymes. They were ligated and transformation of Top10 cells was performed (Fig. 
3.2). One positive colony was observed. Plasmid isolation was performed for this 
colony and obtained plasmid was digested and checked through agarose gel 
electrophoresis (Fig. 3.3). 
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              Figure 3.2 : Cloning results of MEFV-d2 (M: Marker, Lane 2,4: Negative 
colony for insert, Lane 3: Positive colony for insert, Lane 6: 
Negative control.) 
 
 
                  Figure 3.3 : Digestion of obtained plasmid from selected colony (M: 
Marker, Lane 1: Digested construct, Lane 3: Uncut 
construct). 
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3.4 Results of pCMV-myc plasmid via NcoI restriction enzyme 
Fluoresence staining was not worked after transfection assay so that we doubted that 
our vector was C-terminal, not N-teminal. To understand that we found a different 
enzyme site (NcoI) between two vector and cut and checked on agorese gel (Fig. 
3.4). As a result of this, we found out that our plasmid was C-terminal. That was an 
obstacle to form a fusion protein with myc-tagged due to including of a stop codon  
in our MEFV-d2 pcr product. Therefore we decided to use commercial cloned 
MEFV-fl and MEFV-d2-GFP tagged plasmids. 
 
 
Figure 3.4 : Observation of digested pCMV-myc vector (M: Marker,   Lane 1: 
Digested vector, Lane 2: Uncut vector). 
 
3.5 Results of plasmid digestion 
Used constructs were checked via XhoI restriction enzyme. After digestion reaction, 
plasmids were run on an agorase gel and digested constructs were monitored under 
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UV light. Construct of MEFV-fl-GFP is 8.9 kb and MEFV-d2-GFP is 7.9 kb (Fig. 
3.1). 
 
        Figure 3.5 : Digested constructs (Lane 1: Marker, Lane 2: MEFV-fl-GFP, 
Lane:MEFV-d2). 
 
3.6 Results of differentiation assay 
In order to differentitate HL-60 cells to neutrophil-like cells, they were incubated 
with 1.75% DMSO for six days. After the incubation, cells were visualized under 
confocal microscope. 2x105 cells/mL, 1.5x105 cells/mL, 1x105 cells/mL and 0.5x105 
cells/mL were used as initial cell numbers and 15,4%, 17%, 23,12% and 40,71% of 
the cells were observed to be differentiated to neutrophil-like cells, respectively (Fig. 
3.2). According to these results, 0.5x105 cells/mL was determined as initial cell 
number. Moreover, flow cytometry assay was performed to determine the 
differentiation rate in which CD44 antigen was chosen. CD44, which is a cell-
surface glycoprotein involved in cell–cell interactions, cell adhesion and migration, 
is expressed in many different cell types including hemopoietic cells. DMSO-
induced differentiation towards neutrophils causes downregulation of CD44 from the 
surface of cells compatible with a similar reduction in CD44 expression during 
normal granulopoiesis [99,100]. For this reason, untreated HL-60 and DMSO-
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induced HL-60 cells were compared according to CD44 expression. As a result, 
CD44 loss was found in DMSO-induced HL-60 cells compared to untreated cells. 
 
 
 
Figure 3.6 : DMSO induction of HL-60 cells. (A) DAPI staining of differentiated 
HL-60 cells. (B) Differentiation rate with regard to incubation length 
and initial cell number. 
 
 
Figure 3.7 : CD44 expression analysis of undifferentiated and differentiated HL-60 
cells. 
 
 
A B 
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3.7 Results of transfection and protein localization assay 
3.7.1 Transfection results of HL-60 cells  
After twenty-four hours, cells were examined via confocal microscopy and it was 
observed that MEFV-fl-GFP was localized in cytoplasm of the cell and MEFV-d2-
GFP was localized in nucleus (Fig. 3.8). 
 
                        Figure 3.8 : Localization of MEFV transcripts into HL-60 cells. 
 
3.7.2 Transfection results of differentiated HL-60 (Neutrophil-like) cells 
After twenty-four hours, cells were examined via confocal microscopy and it was 
observed that both of MEFV-fl-GFP and MEFV-d2-GFP were localized in 
cytoplasm of neutrophil-like cells (Fig. 3.9). 
 
3.7.3 Western Blotting Results of Protein Localization 
Double transfections of MEFV-fl-GFP and MEFV-d2-GFP to HL-60 and dHL-60 
were performed. After 24 hours, total, cytoplasmic and nuclear proteins were isolated 
from both untreated and treated cells. According to western blotting results, we 
detected that we were not able to separate cytoplasmic and nuclear zones (Fig. 3.10). 
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Figure 3.9 : Localization of MEFV transcripts into neutrophil-like cells. 
 
 
 
 
 
 
 
 
Figure 3.10 : Western Blotting results of MEFV-fl and MEFV-d2 localization in 
undifferentiated and differentiated HL-60 cells (W: Total protein, C: 
Cytoplasmic protein and N: Nuclear protein). 
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4. DISCUSSION AND CONCLUSION 
 
The gene for FMF, MEFV, encodes the protein pyrin that is known to have a 
function in inflammation and apoptosis. Pyrin isoforms found have different cellular 
localization in different cells such as monocytes and neutrophills. Furthermore a 
specific transcript of MEFV that lacks the exon 2, which also translates into pyrin 
isoform, was previously shown to have higher expression in FMF patients compared 
to controls  by our group (Kireçtepe et al., 2011). 
In this study, we wanted to investigate the localization of exon 2-spliced isoform of 
MEFV and compare to full-length pyrin in neutrophil-like cells to have an 
understanding of its role in inflammatory cells. For this purpose, two GFP-tagged 
plasmids which are MEFV-fl-GFP and  MEFV-d2-GFP were used and transfected to 
HL-60 cell line first, and their localization were detected with confocal microscope. 
Subsequently, HL-60 cells were differentiated to  neutrophil-like cells via DMSO. 
These cells were also transfected with same plasmids and proteins were observed 
through confocal microscopy technique. 
The present study shows that MEFV-fl-GFP was localized in cytoplasm of the cell 
and MEFV-d2-GFP was concentrated in nucleus of HL-60 cell line. Our results are 
consistent with three previous localization studies carried out with different cell lines 
(Tidow et al., 2000, Papin et al., 2000 and Cazeneuve et al., 2003). On the other 
hand, both MEFV-fl-GFP and MEFV-d2-GFP were localized in cytoplasm of 
neutrophil-like cells which further support the hypothesis of its pathologic role in 
inflammation. 
It is well known that cellular levels of interacting proteins and cell-dependent 
functions may affect subcellular localization of protein isoforms. Phosphorylation 
can alter localization of proteins or glycosylation also affect the nuclear localization 
of NLS containing proteins [101].  Accordingly, 14.3.3 proteins (potent antiapoptotic 
factors), which control intracellular signaling, cell-cycle control and apoptosis, 
interacts with pyrin-fl but not pyrin-d2 through three serine residues located in exon 
2. Jeru et. al. showed that this interaction caused the full-length pyrin retaining in the 
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cytoplasm. Further the lack of interaction with the pyrin-d2 isoform resulted in 
protein translocation to the nucleus which required phosphorylation at exon 2 sites 
for this interaction. Thus cell-specific posttranslational processing and/or protein–
protein interactions, may ultimately determine subcellular localization relating to 
pathologic functions in different cell types. According to this study,  it will be 
important to investigate the phosphorylation effects in our neutrophil-like cells that 
could have been altered so that the exon 2 deleted form retained in the cytoplasm. 
Thus cell-specific posttranslational processing and/or protein–protein interactions, 
may ultimately determine subcellular localization relating to pathologic functions in 
different cell types.  
However it is also possible that the general localization pathway could have been 
altered. Previous studies showed that pyrin-d2 mainly localizes to the nucleus, in 
contrast to the cytoplasmic localization of pyrin-fl (Papin et al., 2000). A nuclear 
localization signal is created by the alternative splice event which leads to the 
adjacent of the domains encoded by exons 1 and 3. This splice junction does not 
comport with known NLS motifs. Maybe nuclear import of pyrin-d2 occurs via a still 
unidentified receptor-mediated pathway or via its association with another protein 
that contains an NLS. A domain encoded by the exon 1–exon 3 junction was 
revealed to be necessary but not sufficient for targeting pyrin-d2 to the nucleus, it is 
not unable to functionally substitute for an NLS. Therefore this domain may be 
required for the activity of an NLS-like motif located elsewhere in pyrin-d2. 
Understanding the proteins that interact with the exon 2-deleted but not the full-
length pyrin protein and their functions may lead to identification of mechanism 
involved in nuclear import and FMF disease. 
This study has some weaknesses such as the lack of using other cell types. 
Monocytic cell line (i.e. THP-1, U937) which has MEFV expression and is involved 
in inflammation, should be transfected with this MEFV constructs to compare the 
localization states of pyrin isoforms with neutrophil-like cells. 
To confirm this findings, protein detection was done via western-blotting but 
cytoplasmic and nuclear extraction was unsuccessful so that it should be repeated 
again by using other methods and also to support this study, the localization of pyrin-
fl and pyrin-d2 can be examined in an infection model in vitro. 
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APPENDIX A 
 
Table A.1 : Laboratory equipment 
Precisa 620C SCS Balances 
Precisa BJ 610C 
Centrifuges Thermo Scientific MICROCL 17 
 Allegra 25R Centrifuge Beckman 
Coulter 
Beckman Coulter Microfuge®18 
Thermo Electron Corporation IEC CL10 
Labogene ScanSpeed 1730R 
Pipettes Thermo Finnpipette 2µ 20 µL 200 µl, 
1000 µl 
Thermo Cycler  Techne 512 
Corbett PalmCycler 
Vortex HerdolphReax top 
Heat Block                                                  Dri-Block® DB-2D- Bibby Scientific 
Ltd 
pH Meter Mettler Toledo MP220 
Spectrophotometer NANODROP- Thermo Scientific 
Transilluminator  Biorad UV Transilluminator 2000 
Examination Gloves                                 BROCHE 
Electrophoresis Systems  E – C mini cell primo EC320 
BIO-RAD Mini-PROTEAN® Tetra Cell 
Flow Cytometer BD Accuri C6 
Microplate Spectrophotometer BIO-RAD Benchmark Plus 
Transfer System BIO-RAD Trans-Blot Turbo Transfer 
Incubator with CO2 BINDER 
Nitrogen Tank Air Liquide 
 50 
Shaker Forma Orbital Shaker-Thermo Electron Corporation 
Light Microscope Olympus CH30 
Hemacytometer FisherLab Scientific, 0267110 
High Pressure Steam Sterilizer TOMY SX-700E 
Ice Machine Scotsman AF 10 
Freezers Vestel (+4oC) 
Arçelik (-20oC) 
Sanyo (-80oC) 
Confocal Microscope Leica TCS SP2 SE  
Kodak Medical X-ray Processor Kodak 
Microwave Arcelik MD582 
Cell Strainer BD 
Tissue Culture Flask  Greiner bio-one CELLSTAR® 25 cm2, 
75 cm2 
Culture Plate Greiner bio-one CELLSTAR®                         
6 , 24, 96 well 
Vacuum Filtration System SARSTEDT 500mL 
Syringe Filtre TPP 0,22 µm 
Serological Pipette                                     Greiner bio-one CELLSTAR® 5, 10, 25 
ml 
Petri Dishes Isolab 
Centrifuge Tubes Greiner bio-one 
Axygen 
Nitrocellulose Transfer Packs BIO-RAD 
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APPENDIX B 
 
Table B.1 : Chemicals 
 Acetic Acid                                                 Riedel-de Haën 
 Agarose AppliChem 
 Boric Acid Amresco 
 dNTP Fermentas 
 Betaine Sigma Aldrich 
 EDTA AppliChem 
 Ethanol Merck 
Sigma Aldrich 
 EtBr Amresco 
 SafeView DNA Stain ABM 
 MgCl2 Fermentas 
 Primers IDT DNA 
 Tris Base Amresco 
 10X PCR Buffer Fermentas 
Invitrogen 
 Ampicillin Sigma Aldrich 
 Tryptone  BDH Laboratory 
 Yeast Extract Merck 
 NaCl Fluka 
 LB Agar Biomatik 
 Glycerol Fluka 
 Culture Media Lonza 
 Fetal Bovine Serum (FBS) Lonza 
 Penicilin/Streptomycin   Thermo Scientific 
 Poly-L-Lysine Sigma Aldrich 
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 DAPI Invitrogen 
 Trypan blue Sigma Aldrich 
 Dimethyl sulfoxide (DMSO) Fiedel-de Haën 
 Phosphate Buffered Saline 
(PBS) 
Gibco 
 SDS AppliChem 
 TEMED AppliChem 
 Ammonium persulphate 
(APS) 
Sigma Aldrich 
 Acrylamide/Bis Solution BIO-RAD 
 Bromophenol Blue Merck 
 Tween-20 AppliChem 
 Bovine Serum Albumin 
(BSA) 
Sigma Aldrich 
 Mounting Medium Sigma Aldrich 
 Alexa Flour 488 goat anti- 
mouse 
Invitrogen 
 c-Myc Mouse Monoclonal 
Antibody 
Invitrogen 
 Mouse monoclonal tGFP 
antibody, HRP conjugated 
OriGene 
 Histone H3 Rabbit 
Monoclonal Antibody 
Cell Signaling 
 Β-Actin Rabbit Monoclonal 
Antibody 
Cell Signaling 
 Anti-Human PE-CD44 
Antibody 
BD 
 Isopropanol Fluka 
 Anti-Rabbit IgG-HRP Linked 
Antibody Cell Signaling 
 HCl AppliChem 
 Methanol Riedel- de Haёn 
 20X LumiGLO® Reagent 
and 20X Peroxide Cell Signaling, 7003 
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Table B.2 : Enzymes 
 
BglII NEB 
XhoI NEB 
NcoI Fermentas 
Taq DNA Polymerase Fermentas 
Invitrogen 
 
 
(a)                                            (b)                                         (c) 
             
 
Figure B.1: Markers: (a) Gene Ruler 1 kb DNA Ladder (Fermentas). (b) 2-Log DNA 
Ladder (NEB). (c) BLUelf Prestained Protein Ladder (GeneDirex). 
 
 
Table B.3 : Commercial Kits 
High Pure PCR Product Purification 
Kit 
Roche 
Rapid DNA Dephos & Ligation Kit Roche 
High Pure Plasmid Isolation Kit Roche 
EndoFree Plasmid Maxi Kit Qiagen 
Genopure Plasmid Midi Kit Roche 
Restore Western Blot Stripping Buffer Thermo Scientific 
ProteoJET™ Mammalian Cell Lysis 
Reagent 
Fermentas 
cOmplete Lysis-M Kit EDTA-free Roche 
Quick Start Bradford Protein Assay BIO-RAD 
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Kit 
Amaxa® Cell Line Nucleofector® Kit 
V 
Lonza 
NE-PER Nuclear and Cytoplasmic 
Extraction Reagents 
Thermo Scientific 
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APPENDIX C 
 
Preperation of Buffers 
 
Table C.1 : LB Media 
 100mL 250mL 
Tryptone (g) 1 2.5 
Yeast extract (g) 0.5 1.25 
NaCl (g) 1 2.5 
 
Table C.2 : 10X TAE Buffer 
 Amount 
Tris-base 24.2 g 
Acetic Acid 5.71 mL 
EDTA 25.4 mL 
dH2O Add to 500 mL 
 
Table C.3 : TE Buffer 
 Amount 
Tris-base 10 mM 
EDTA 1 mM 
dH2O Add to 1 L 
 
 
Table C.4 : 10X TBS Buffer 
 Concentration Amount 
Tris-base 25 mM 3 g 
Glycine 192 mM 14,4 g 
Methanol 20 % 200 mL 
SDS 0,05 % 0,05 g 
dH2O  up to 1 L 
 
Table C.5 : TBS-T Buffer 
 Concentration Amount 
TBS 1X 1 L 
Tween-20 0,05 % 500 µL 
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Table C.6 : SDS-polyacrylamide gel 
4% Stacking Gel  
Acrylamide/Bis-acrylamide 0.67 mL 
20% SDS 0.025 mL 
0.5 M Tris-HCL, pH 6.8 1.25 mL 
dH2O 3.075 mL 
10% APS 0.025 mL 
TEMED 0.005 mL 
12% Separating Gel  
Acrylamide/Bis-acrylamide 4 mL 
20% SDS 0.05 mL 
1.5 M Tris-HCL, pH 8.8 2.5 mL 
dH2O 3.4 mL 
10% APS 0.05 mL 
TEMED 0.005 mL 
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APPENDIX D 
 
Plasmids 
 
 
 
Figure D.1: pTZ57R/T (Thermo Scientific) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
 
 
 
 
Figure D.2: pCMV-Myc-N (Clontech) 
1         2          3           4          5          6         7         8         9       10 
     11 
 58 
    
 
 
 
 
 
Figure D.3: pCMV-Myc-C (Clontech) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure D.4: pCMV6-AC-GFP-MEFV-FL (OriGene) 
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Figure D.5: pCMV6-AC-GFP-MEFV-d2 (OriGene) 
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